Compare Royal Caribbean Cruises Ltd (RCL) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Tilray Brands Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $282.26 (market cap $75.26B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Royal Caribbean Cruises Ltd is far larger — about 141.9× Tilray Brands Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Tilray Brands Inc for 31 Days on average.
| RCL | TLRY | |
|---|---|---|
Market Cap | $75.26B | $530.54M |
Volume | 1,958,628 | 9,099,075 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $17.20 |
52-Week Low | $230.30 | $3.54 |
Typical Hold Time | 85 Days | 31 Days |
Enterprise Value | $97.91B | $684.46M |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $281.39, down 0.35% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with 2025 revenue of $17.93B and net income of $4.27B, representing a 23.54% margin. Recent Q2 2026 earnings beat expectations at $4.21 EPS versus $3.98 expected, while the company expands into resorts through a $3B Sandals stake acquisition announced September 2026.
RCL presents a compelling growth story with improving profitability and strategic expansion, though elevated valuation multiples and high debt levels warrant caution. Analyst consensus remains bullish with a $346.67 price target representing 23% upside potential, but investors should monitor execution risks from the Sandals integration and sensitivity to fuel costs projected at $1.34B for 2026.
TLRY trades at $3.59, down 3.36% on the day and near 52-week lows, with a bearish technical signal. The company reported revenue of $821.31M for 2025 but posted a net loss of -$2.19B, missing earnings expectations for four consecutive quarters. While analyst consensus shows 70% hold ratings, the stock faces significant profitability challenges with negative margins and cash flow concerns despite some revenue growth projections.
The outlook remains challenging with persistent losses and negative cash flow, though the stock trades at discounted valuation multiples. Key risks include ongoing profitability struggles and cannabis regulatory uncertainty. Potential catalysts include upcoming Q1 2027 earnings on October 8, 2026, and potential marijuana reform developments that could benefit the company's positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
